Wezenla 130 mg/26 ml, Konzentrat zur Herstellung einer Infusionslösung

7680701870015 CH-70187 Konzentrat

Associated product:

WEZENLA 130 mg/26 ml conc perf 130 mg 1 pce

No image available

Article details

Package size
1
Selling units
1
Measure
Durchstechflasche(n)
Galenic form
Konzentrat
Galenic group
Tinkturen/Desinfektion

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics
Allemand
29/04/2026
Summary of Product Characteristics
Français
29/04/2026
Summary of Product Characteristics
Italien
29/04/2026

Detailed composition

Substance Quantity Type Category
ustekinumabum
130.0 MG Substance Wirkstoff (Principe actif)
saccharum
- Substance HNIDK
histidinum
- Substance HNIDK
histidini hydrochloridum monohydricum
- Substance HNIDK
methioninum
- Substance HNIDK
polysorbatum 80
- Substance HNIDK
dinatrii edetas
- Substance HNIDK
natrii hydroxidum
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK
natrium
0.097 MG Substance HBESI

Reimbursement information

Public price
CHF 1540.15
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/05/2026

Authorization holder

Amgen Switzerland AG

6343 Risch

Authorization information

Swissmedic authorization number
70187
Drug name
Wezenla, Konzentrat zur Herstellung einer Infusionslösung
Galenic form
KOINF
ATC Code
L04AC05
Authorization status
Z
Dispensing category
B
First authorization
23/07/2025
Authorization expiration date
22/07/2030
IT Number
07.15.0.
Domain
Human medicine
Field of application
Morbus Crohn, Ulcerative Colitis

Package details

Description (FR)
WEZENLA 130 mg/26 ml conc perf 130 mg 1 pce
Description (DE)
WEZENLA 130 mg/26 ml Konz Inf 130 mg 1 Stk
Market launch
29/04/2026
Narcotic (BTM)
No
Buy us a coffee Explore the data